Roche said it will expand existing sites and construct new U.S. manufacturing and R&D infrastructure in areas such as gene therapy and cardiometabolic disease. The plans follow U.S. capital expenditure announcements from several big pharmaceutical companies.
The post Roche Commits to $50B in U.S. Manufacturing and R&D Investments as Pharma Tariffs Loom appeared first on MedCity News.
